We have previously partnered our data in multiple multi-million dollar drug discovery collaborations with pharma on a bespoke basis.

Built, running, validated at TRL-4: 204 autonomous hours, zero human intervention, 145K+ observations, and 486 verified operating points. We’ve proven biological performance across 700+ plant experiments, 60+ species, and 99% survivorship. Demand is validated by 25+ signed MOUs / pilot-waitlist organizations and inclusion in $10M+ of DOE, USDA, and NASA grant submissions. Raising $3M to deploy.

No LOI, as the startup is just being formed. But had informal discussions with Schneider, ABB etc and they showed interest in having a CESS system for AIDCs, and also had discussions with CALSTART where they are introducing us to a defense platform.

We have initiated a paid pilot with a Agricultural Phage Company to produce their phage in our cell-free systems.  Clinical Parternship: Terms signed with Louisiana's largest hospital system (Ochsner) for a  pilot towards compassionate use trials and platform subscription accesss (MoU in draft) Signed collaborative research agreement with USDA for Aquaculture pathogens.

* 2 of top 15 pharma / life science companies confirmed PoC study * 3 of top 15 PharmaCo + decacorns quoted in addition;  * 2 Nobel prize winning labs as customers * >€ 2.5m in approval stages * global top 5 universities & research hospitals as paying customers

First revenues in with large industry MOUs and LOIs. From USA, EU and Australia

We have a paid pilot ongoing with a top-5 veterinary pharma and are negotiating with another top-5 veterinary pharma on exclusivity in animal health with low 8 digit ARR potential by 2030. GSK, Sanofi, and others want to see more in vivo data.  Established collabs with Karolinska Institute, Oxford University, Trinity College Dublin for in vivo studies.

Swan Genomics is developing a plasmonic nanoantenna-based single-molecule DNA sequencing platform that addresses a fundamental bottleneck in genomic medicine: the cost, speed, and accessibility of sequencing at clinical and research scale. While the platform is pre-revenue with a product launch hori

Traction is market pull and expert validation, not revenue. Endpoint AI inference and learning is an open gap: existing accelerators fail on power and cost. 2 signed Design Partner agreements. Validation: Silicon Catalyst, CHIPS Act via Stanford, Most Innovative Paper at ISCA 2025 energy efficiency workshop, 1st chip at TSMC, 3 U.S. patents, seed term sheet at $20M pre-money.

$160M in LOIs split between $90M (10-year offtake) for product and $72M for a retrofit

* Over $700k in NRE revenue * In deep discussion for pilots with multiple corporates * Validated market entry through customer interviews * One potential customer looking to invest and offtake at larger scale once lead is found

400k$ pre-purchases in 2025/26 on our air capture application via Milkywire (EQT, Klarna) - top 5% of DAC. We are now scaling the same core tech to gas-power and data center net-zero infrastructure, unlocking a $100M pipeline with hyperscalers, turbine OEMs, and utilities across the US, EU, and APAC. EDF collaboration and Temasek Liveability Challenge finalist (8 of 1,500) round out the validation

Cetos Water is a Columbia University spinout building the infrastructure layer to turn the world’s most concentrated industrial wastewater into clean water and critical minerals — helping heavy industry reduce disposal, unlock new water supply, and keep production running in water-constrained environments. Our core breakthrough is a membrane-less, non-evaporative extraction process that treats hypersaline brines conventional systems can't handle, including streams far beyond the salinity limits of membrane systems. By avoiding boiling corrosive brines, we deliver a solution that is 70% more energy efficient and 50% more capital efficient than state-of-the-art technologies. Our customer acquisition strategy is focused on production-critical industries where water is becoming a direct operational and permitting constraint, including oil & gas, mining, power generation, and data centers. We are partnering with operators through paid pilots and testing engagements, using early technical validation, rising disposal costs, and tightening regulatory pressure to drive commercial adoption.

Signed 6 MOUs across the build environment supply chain (e.g., construction companies, designers, precast concrete producers, cement producers) including ACCIONA, AECON, Fast+Epp, Titan Cement, Molins Cement, and Grand Forks Concrete.  We have our first revenue: a $50,000 pilot service contract with Grand Forks Concrete, structured as a joint venture to cost-share our 100 TPA and 30,000 TPA FOAK.

Demand for BlueSCM is outpacing our FOAK development. We have aligned 4 paid projects utilizing our SCM, and are actively building larger 1-ton/day systems to fulfill these projects. We're in phase 2 with anchor pilots w Ozinga & Heidelberg Materials, with ASTM validation of our material targeted mid-May, and in an active, $60k waste offtake pilot with UPM/Montes del Plata. Round 50% secured.

Currently we have a subscriber list of 40k who are ready to buy the consumer products our company will produce (creatine monohydrate). That is the most immediate specialty nitrogen product we can make and it will be ready for sale within 12 months. That market is growing at 20% per year. For energetics, the market is currently $30B and growing at 5% per year.

We have no revenue or signed TiCore LOIs yet. Customer discovery around off-grid AI factories showed a clear pain: AI operators can get GPUs and capital faster than live power. TiCore turns that demand into a smaller, repeatable power-and-compute unit. Next milestone: first 10 MW design partner / LOI.

Through my time at Exowatt I have had hundreds of conversations with data center customers, independent power producers, developers, and utilities. Data centers are increasingly focused on time-to-power, with behind-the-meter natural gas serving as the dominant bridge solution. American Supercritical provides 50% more power from every gas turbine, without additional emissions or water use.

Permeon is building a new autonomous O&G producer in Calgary with a team of industry veterans. We're rolling up small/inefficient producers and automating them with agents and robots. Calgary roll-ups like Spur Petroleum and Saturn Oil unicorned in 4-5 years; vertically-integrated frontier tech/talent can beat that 10x. Venture lets Permeon acquire counter-cyclically to the oil price and buy/automate wells at low multiples from depressed producers, and then harvest the efficiency/price gains to re-invest into the next cycle. The long-term plan is to keep riding macro cycles and automation efficiencies to fold in small/medium E&Ps and consolidate into a big operator.

Our technology, the Polomac, enables a cost-efficient fusion solution by eliminating the need for tritium production, significantly reducing operational complexity and cost. Our customer acquisition strategy focuses on forming early partnerships to develop a first pilot plant for industrial heat. From there, we scale toward electricity generation.

Shipped 1,000 Nailbot 1.0 units, $208K+ in revenue, hit #1 Amazon New Release, and proved repeat usage: 60% print their own content, power users print 100x/month. Confidential multi-million dollar 2-year NBCU deal across 3 franchises covering co-branded hardware, standalone consumables, digital content, and activations validates that we've cracked multi-gen appeal with fandom and distribution.

OBSIDIA has advanced to the second round of evaluation for a $34M NIST CRDO award, and is preparing beta REELScan deployments with ParPro and SparkFun as we move toward first commercial units by year-end. LOI - tate of Colorado, The Charles Stark Draper Laboratory, Naval Surface Warfare Center - Crane, SMT Corp, Kostas Research institute for Homeland Security.

We have reduced the cost of a tFUS system from $200,000 to $450 ($150 BOM). We have begun selling the devices, doing over $100,000 of sales in the first day alone.  On the neuroscience, we are the first team that we know of to successfully up regulate the frontoparietal network, which is the neural correlate of lucid dreaming. Now we have shown causation and successfully increased lucidity.

Recent spacenews article on heels of space force support memo. CRADA with test lab for testing of L-182 radio. Early customers identified and lined up for radio. Demo with Space Force in Q4 2026. Several MM dollar PO's for radio platform currently in discussion.  Separate X-band SDR project in several customer discussions including top aerospace firms, none we can publicly discuss yet.

MIC is pre-rev but demand is structurally validated. BCI drone racing events already exist in the US, and the global BCI market is projected at $5.4B by 2030. With 1B+ people living with disabilities (WHO), neural interfaces are an accessibility imperative.  For us, Singapore's extracurriculum licensing model gives us a direct institutional sales channel from day one; in talks with 1 school.

HeadFirst is developing a rapid, saliva-based concussion screening test for point-of-care use, delivering results in under 10 minutes without lab infrastructure. Our core breakthrough is proprietary chemistry that enables visual detection of low-concentration biomarkers in saliva on a portable, single-use assay, which has historically required instrumentation. We are initially applying this to traumatic brain injury given the significant unmet need, enabling real-time decision-making in athletic, clinical, and military settings. On the commercial side, we are pursuing a B2B distribution strategy with sports organizations, clinics, and healthcare providers, supported by early LOIs and pilot programs to drive adoption.

We are in active pre-production with NuLoupes, with units already used by surgeons in live procedures across multiple specialties. We have completed full cases start-to-finish without reverting to traditional optics, validating performance and workflow in real OR settings. Traction has been entirely organic, with inbound interest from 35+ hospital systems.

We have an active, enrolling Phase II clinical trial to prove efficacy https://clinicaltrials.gov/study/NCT07304024. A modest publicity bump from winning a pitch contest last week doubled the number of trial volunteers (we currently have 130+). We are going to market via Montana's SB535 (rules finalized as early as next week). We have a first customer lined up & dozens of patients referred.

Corvita has a signed LOI with First Steps Humanitarian Society for four ARK Incubators. We have committed clinical advisors from some of Canada's largest hospitals who will become Principal Investigators on pilot studies for clinical validation and act as gateways into their respective hospitals after commercialization.

Experienced management team with deep knowledge of the space.  Demo/POC agreement with JLL.  Extensive technology exchanges with vendor, Nokia.  Spoken with 40 robotic companies validating connectivity challenges/plans for 5G.  AI Agents framed out and under development. Day 1 of model starts with close of seed Round.

20 robots deployed with leading contractors and factories, including PCI, Hensel Phelps, Turner, DPR, and others. In Q1 2026, we signed deals exceeding $1M, with deliveries already underway in Q2. Based on the current pipeline and sales cycle, 2026 revenue is expected to exceed $3M. In parallel, a pilot project with a major U.S. builder is underway, with potential for deployment of over 100 robots

$250k in revenue across three contracts in our first year, including 2 deployments to >5000m. $500k revenue to date in 2026, on track for $1M in our second year. $100M potential revenue in top of funnel pipeline.

We have a working prototype protected by two filed patents (PCT), along with 6 LOIs, one completed paid project, and two more scheduled. In addition, we have interviewed over 300 potential customers and experts to validate demand and identify the best segments for our market entry.

We've spent the last several months engaging in conversations with over 50 manufacturers & AI companies, and have over $1M in requests for us to satisfy

We are actively engaging with Argentina’s national space ecosystem and broader Latin American space programs to secure early customers. The region is experiencing growing satellite development activity but lacks sufficient domestic launch capacity, which creates a clear medium-term market opportunity for our services. We have validated demand through ongoing discussions with institutional and comm

LOIs signed for over 40 spacecraft, representing >$50M in potential revenue. Protoflight hardware developed for reaction wheels, torque rods, IMUs, magnetometers, and core avionics. Flight and ground software developed and running.

OEM channel locked at founding: CPS Group (€25M sales, 20,000+ machines in 50+ countries) is our distribution seat, founder sits on its NIS2 executive body and runs CPS US (CAGE-code defense sub), so every crane shipped is a FUSE seat. Operators burn ~$180K/yr per machine in manual labor → sub-9-month payback. Army's M-MET concept (AUSA 2025) targets our exact class; fielded version running today.